01—Abstract
Summary
Summary of the 10-K filed February 20, 2025. Cited figures are marked; the original filing is the authoritative source.
Danaher Corporation (DHR) reported flat total sales for the fiscal year ended December 30, 2024, with a 1.5%a decrease in core sales.
This performance was influenced by a 2.0% boost from acquisitions, which partially offset declines in the Biotechnology and Life Sciences segments, while the Diagnostics segment showed growth. Net earnings from continuing operations declined to $3.9 billionb from $4.2 billion in the prior year, impacted by intangible asset impairments and increased operating expenses. The company's strategic priorities remain focused on strengthening competitive advantage through the Danaher Business System (DBS), enhancing its portfolio via strategic capital allocation, and attracting top talent.
Looking ahead, Danaher has initiated a cost savings program expected to generate at least $150 millionc in annual pre-tax savings starting in Q1 2025. The company also continues to manage its capital structure, evidenced by significant share repurchases totaling $6.0 billion in 2024. Despite a challenging macro-economic environment, including global economic uncertainty and inflationary pressures, Danaher's diversified business model across life sciences, diagnostics, and biotechnology sectors provides a degree of resilience.
02—Key points
Key Highlights
- Total sales remained flat year-over-year for the fiscal year ended December 30, 2024, while core sales decreased by 1.5%.
- Net earnings from continuing operations decreased to $3.9 billion from $4.2 billion in the prior year, impacted by intangible asset impairments and higher operating expenses.
- The company initiated a cost savings program in Q1 2025 targeting at least $150 million in annual pre-tax savings.
- Danaher repurchased approximately $6.0 billion of its common stock in fiscal year 2024.
- The Biotechnology segment experienced a 6.0% sales decline, primarily due to decreased core sales in bioprocessing, while the Diagnostics segment saw a 2.0% sales increase driven by core growth.
- The Life Sciences segment reported a 2.5% sales increase, largely due to acquisitions, but faced a core sales decline.
- Geographically, North America showed strength with increased sales in developed markets, while high-growth markets, particularly China, experienced a decline in core sales.
- The company ended the year with $2.1 billion in cash and cash equivalents and maintained a strong liquidity position with a $5.0 billion revolving credit facility.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2024, Danaher Corp kept $0.16.
- Revenue$23.88B100.0%
- Cost of revenue−$9.67B40.5%
- Gross profit$14.21B59.5%
- Operating costs−$9.34B39.1%
- Operating income$4.86B20.4%
- Interest, other & tax−$964.0M4.0%
- Net income$3.90B16.3%
Where FY2024 revenue went
$23.88B- Cost of revenue: $9.67B, 40% of revenue
- SG&A: $7.76B, 32% of revenue
- Net income: $3.90B, 16% of revenue
- R&D: $1.58B, 6.6% of revenue
- Interest, other & tax: $964.0M, 4.0% of revenue
Kept 16% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2024filed February 20, 2025Financial Statements
FY2024 against FY2023
| Line item | FY2024FY2023 | Change |
|---|---|---|
| Revenue | $23.88B$23.89B | −0.1% |
| Cost of Revenue | $9.67B$9.86B | −1.9% |
| Gross Profit | $14.21B$14.03B | +1.2% |
| R&D Expenses | $1.58B$1.50B | +5.4% |
| SG&A Expenses | $7.76B$7.33B | +5.9% |
| Operating Income | $4.86B$5.20B | −6.5% |
| Net Income | $3.90B$4.74B | −17.8% |
| EPS (Basic) | $5.33$6.44 | −17.2% |
| EPS (Diluted) | $5.29$6.38 | −17.1% |
| Shares Outstanding (Basic) | 731.00M736.50M | −0.7% |
| Shares Outstanding (Diluted) | 737.20M743.10M | −0.8% |
05—Questions
Frequently Asked Questions
What was Danaher's overall financial performance in the fiscal year ended December 30, 2024?
Danaher reported flat total sales for the fiscal year, with core sales declining by 1.5%. Net earnings from continuing operations decreased to $3.9 billion, down from $4.2 billion in the prior year, primarily due to intangible asset impairments and higher operating expenses.
What are Danaher's key strategic priorities and how is it addressing current economic challenges?
Danaher's strategic priorities are strengthening its competitive advantage through the Danaher Business System (DBS), enhancing its portfolio through strategic capital allocation, and attracting exceptional talent. To address economic challenges, the company has initiated a cost savings program expected to yield at least $150 million in annual pre-tax savings, beginning in the first quarter of 2025.
How did Danaher's business segments perform?
The Biotechnology segment saw a 6.0% decrease in sales, largely due to lower bioprocessing demand. The Life Sciences segment experienced a 2.5% sales increase driven by acquisitions, though core sales declined. The Diagnostics segment showed resilience with a 2.0% sales increase, supported by core growth, particularly in North America.
What is Danaher's approach to capital allocation and shareholder returns?
Danaher actively manages its capital structure. In 2024, the company repurchased approximately $6.0 billion of its common stock. The company also declared a regular quarterly cash dividend, demonstrating a commitment to returning capital to shareholders.
06—Continue